During the last session, Kala Pharmaceuticals Inc. (NASDAQ:KALA)’s traded shares were 0.57 million, with the beta value of the company hitting 0.95. At the end of the trading day, the stock’s price was $0.68, reflecting an intraday gain of 9.48% or $0.06. The 52-week high for the KALA share is $6.77, that puts it down -895.59 from that peak though still a striking 13.24% gain since the share price plummeted to a 52-week low of $0.59. The company’s market capitalization is $48.98M, and the average intraday trading volume over the past 10 days was 0.96 million shares, and the average trade volume was 2.00 million shares over the past three months.
Kala Pharmaceuticals Inc. (NASDAQ:KALA) trade information
Kala Pharmaceuticals Inc. (KALA) registered a 9.48% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 9.48% in intraday trading to $0.68 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -12.72%, and it has moved by -20.50% in 30 days. Based on these gigs, the overall price performance for the year is -86.49%. The short interest in Kala Pharmaceuticals Inc. (NASDAQ:KALA) is 5.15 million shares and it means that shorts have 3.84 day(s) to cover.
Kala Pharmaceuticals Inc. (KALA) estimates and forecasts
Statistics show that Kala Pharmaceuticals Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Kala Pharmaceuticals Inc. (KALA) shares have gone down -67.29% during the last six months, with a year-to-date growth rate more than the industry average at 39.27% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 27.30% this quarter and then jump 20.40% in the quarter after that. In the rating firms’ projections, revenue will increase 99.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $3.53 million as predicted by 5 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $4.76 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $2.24 million and $4.22 million respectively. In this case, analysts expect current quarter sales to grow by 57.70% and then jump by 12.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.00%. While earnings are projected to return -9.80% in 2022, the next five years will return 40.90% per annum.
Kala Pharmaceuticals Inc. is due to release its next quarterly earnings between February 23 and February 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kala Pharmaceuticals Inc. (NASDAQ:KALA)’s Major holders
Kala Pharmaceuticals Inc. insiders own 0.97% of total outstanding shares while institutional holders control 51.26%, with the float percentage being 51.76%. RA Capital Management, L.P. is the largest shareholder of the company, while 164 institutions own stock in it. As of Sep 29, 2021, the company held over 10.87 million shares (or 16.60% of all shares), a total value of $28.49 million in shares.
The next largest institutional holding, with 3.66 million shares, is of Blackrock Inc.’s that is approximately 5.60% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $9.6 million.
Also, the Mutual Funds coming in first place with the largest holdings of Kala Pharmaceuticals Inc. (KALA) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.41 million shares. This amounts to just over 2.15 percent of the company’s overall shares, with a $3.69 million market value. The same data shows that the other fund manager holds slightly less at 1.13 million, or about 1.72% of the stock, which is worth about $1.96 million.